Short Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Rises By 5.7%

Aura Biosciences, Inc. (NASDAQ:AURA) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totalling 1,300,000 shares, a growth of 5.7% from the August 15th total of 1,230,000 shares. Based on an average daily trading volume, of 174,700 shares, the days-to-cover ratio is presently 7.4 days. Currently, 3.1% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on AURA shares. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of Aura Biosciences in a research note on Friday. JMP Securities increased their price target on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday. Finally, Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th.

Institutional Trading of Aura Biosciences

Institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. acquired a new position in shares of Aura Biosciences during the 2nd quarter worth $119,000. American International Group Inc. lifted its stake in shares of Aura Biosciences by 27.4% in the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after purchasing an additional 3,782 shares during the last quarter. Virtu Financial LLC bought a new stake in Aura Biosciences in the first quarter worth $144,000. Trexquant Investment LP increased its position in Aura Biosciences by 64.5% during the fourth quarter. Trexquant Investment LP now owns 17,362 shares of the company’s stock worth $154,000 after buying an additional 6,809 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in Aura Biosciences by 39.6% during the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after buying an additional 18,011 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Trading Down 1.0 %

AURA opened at $9.97 on Tuesday. The stock has a fifty day moving average price of $8.58 and a 200 day moving average price of $7.87. Aura Biosciences has a 1 year low of $5.99 and a 1 year high of $12.35. The stock has a market cap of $493.94 million, a price-to-earnings ratio of -5.36 and a beta of 0.35.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.04. As a group, sell-side analysts forecast that Aura Biosciences will post -1.7 earnings per share for the current fiscal year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.